Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001010086

SIGA

SIGA TECHNOLOGIES INC
$3.37 ▲ +0.60%
Prev close $3.35
Market cap$244.3M
26 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SIGA right now — valuation, ownership and activity at a glance.
Market Cap
$244.3M
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$97.5M
Inst. Activity
26 buys / 10 sells
Social Sentiment
33° Cool
SEC Reports
2
Press Releases
1
Price chart 30d +5.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 6, 2026 earnings
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commerc
Jun 30, 2026 Inst.
Qube Research & Technologies — ADD
740,910 shares ($2.7M)
Jun 30, 2026 Inst.
JACOBS LEVY EQUITY MANAGEMENT, — ADD
566,863 shares ($2.1M)
Jun 9, 2026 Insider
Marshall Joseph W III disposed of 7,235 shares
Director @ $4.39 ($31.8K)
Jun 9, 2026 Insider
Marshall Joseph W III was granted 34,169 shares
Director
Jun 9, 2026 Insider
Nabel Gary J. acquired via exercise 24,116 shares
Director
May 8, 2026 SEC
SIGA Technologies filed a DEFA14A supplement to its 2026 proxy statement, correcting errors in Proposal 4 regarding the
DEFA14A — Impact 2/10
May 7, 2026 SEC
SIGA reported Q1 2026 total revenues of $6.2M (down 11% YoY) and a net loss of $3.5M vs $0.4M loss a year ago, driven by
PRESS-RELEASE — Impact 6/10
Analyst ratings
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
Nov 6, 2012WedbushMAINTAINOutperform 57%
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
2 mentions 0 bullish 2 bearish 0 neutral
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 1 neutral · avg impact 4.0/10.Plus 1 press releases.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 11, 2026
Clinical Trial
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
Phase Phase 3 — COMPLETED
Sep 11, 2026
Clinical Trial
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Phase Phase 3 — COMPLETED
Sep 11, 2026
Clinical Trial
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
Phase Phase 2 — COMPLETED
Aug 6, 2026
earnings
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported f
Aug 6, 2026
earnings_calendar
SIGA Q2 2026 Earnings Scheduled — 2026-08-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$0.00$0.00–$0.00———$0.0B—
Next Q$0.00$0.00–$0.00———$0.0B—
Current FY$0.05$0.05–$0.05-84.4%-66.7%0↑ 1↓$0.1B1
Next FY$1.08$1.08–$1.082060.0%+2.9%—$0.2B1
Institutional ownership
Which big funds own SIGA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $97.5M total value (26,765,451 shares) as of 2026-Q2. Top holders: BlackRock,, DIMENSIONAL, VANGUARD. Net buying activity: 26 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.4,186,282$15.2M15.6%—
DIMENSIONAL FUND ADVISORS LP2,719,568$9.9M10.1%—
VANGUARD CAPITAL MANAGEMENT LLC1,712,701$6.2M6.4%—
AMERICAN CENTURY COMPANIES INC1,506,065$5.5M5.6%—
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1,474,817$5.4M5.5%ADD +48.9%
GEODE CAPITAL MANAGEMENT, LLC1,417,092$5.2M5.3%ADD +30.9%
AQR CAPITAL MANAGEMENT LLC1,245,992$4.5M4.6%ADD +39.7%
STATE STREET CORP1,133,989$4.1M4.2%—
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC914,047$3.3M3.4%—
Qube Research & Technologies Ltd740,910$2.7M2.8%ADD +78.5%
Recent position changes
FundActionPrevCurrentChangeValue
Qube Research & Technologies LtdADD415,104740,910+78.5%$2.7M
JACOBS LEVY EQUITY MANAGEMENT, INCADD291,846566,863+94.2%$2.1M
MORGAN STANLEYADD263,335421,009+59.9%$1.5M
GOLDMAN SACHS GROUP INCTRIM624,903393,007-37.1%$1.4M
Creative PlanningADD168,555275,528+63.5%$1.0M
D. E. Shaw & Co., Inc.TRIM456,385264,900-42.0%$964.2K
VICTORY CAPITAL MANAGEMENT INCTRIM376,571260,062-30.9%$946.6K
UBS Group AGADD104,062181,998+74.9%$662.5K
Man Group plcADD94,513157,348+66.5%$572.7K
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED69,082145,060+110.0%$528.0K
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 35 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
Jun 9, 2026Marshall Joseph W IIIDirectorD7,235$4.39$31.8K
Jun 9, 2026Marshall Joseph W IIIDirectorAWARD34,169——
Jun 9, 2026Nabel Gary J.DirectorEXERCISE24,116——
Jun 9, 2026Nabel Gary J.DirectorD7,235$4.39$31.8K
Jun 9, 2026Nabel Gary J.DirectorAWARD34,169——
Jun 9, 2026DURNAN JAYMIE ADirectorEXERCISE24,116——
Jun 9, 2026DURNAN JAYMIE ADirectorD7,235$4.39$31.8K
Jun 9, 2026DURNAN JAYMIE ADirectorAWARD34,169——
Jun 9, 2026Nemirovsky JulianDirectorEXERCISE24,116——
Jun 9, 2026Nemirovsky JulianDirectorAWARD34,169——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SIGA.
Shares short
3,729,992
Settlement Sep 15, 2026
Change vs prior
+5.0%
Semi-monthly cycle
Days to cover
5.5
At avg daily volume
Of shares outstanding
≈5.2%
Estimate — not % of float
All SIGA filing & press-release reports (3)